SAN DIEGO, Sept. 15, 2014 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") announced that preliminary results of the TearLab Cataract Study were presented today at the XXXIII Congress of the European Society of Cataract and Refractive Surgeons ("ESCRS").
The preliminary results of this ground-breaking study evaluating the relationship of a hyperosmolar tear film on keratometry readings were presented at ESCRS by Doyle Stulting, MD, President of the Stulting Research Center, Woolfson Eye Institute, Atlanta, GA. Dr. Stulting presented the data on behalf of the study investigators, Cynthia Matossian, MD, Alice Epitropoulos, MD, and Greg Berdy, MD.
The study (n=67) demonstrated that hyperosmolar patients demonstrated a wider variation in keratometry calculations between visits relative to the normal osmolar group. In the hyperosmolar group, 16% of hyperosmolar eyes had more than 1 diopter of change in K cylinder values between the first and second visit.
Dr. Stulting noted, "This study demonstrates the importance of evaluating osmolarity during surgical planning in order to ensure that pre-surgical keratometry readings are not compromised by hyperosmolarity of the ocular surface."
The study results will be submitted for publication to the Journal of Cataract and Refractive Surgery.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press release include statements regarding the future potential of the TearLab Osmolarity System and the related impact on our sales. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the SEC on March 17, 2014, and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, filed with the SEC on August 8, 2014. We do not undertake to update any forward-looking statements.
CONTACT: Stephen Kilmer (647) 872-4849 firstname.lastname@example.org